NCT03976258View on ClinicalTrials.gov

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

CompletedOBSERVATIONAL
Enrollment

190

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
HIV InfectionOpioid-use DisorderCardiovascular Diseases
Interventions
DRUG

buprenorphine/naloxone

This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

DRUG

Methadone

This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

DRUG

Naltrexone Injection

This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.

DRUG

Heroin

This is an observational study. Participants using heroin will be enrolled into this group.

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Cleveland

44109

Metrohealth Medical center, Cleveland

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

MetroHealth Medical Center

OTHER

NCT03976258 - Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV | Biotech Hunter | Biotech Hunter